Give us a Call +1 (720) 515-1377

QAD Inc., a leading provider of enterprise software and services, announced today that Aesica Pharmaceuticals S.r.l., the Italian division of Aesica Pharmaceuticals Limited, has upgraded to QAD Enterprise Applications Enterprise Edition (QAD EE). The upgrade helped Aesica meet the deadline for a new serialization regulation for the Chinese market. A recently published case study shares the complete details of the implementation and its benefits.

Aesica is a leading pharmaceutical contract development and manufacturing organization (CDMO). The company, operating in a highly regulated industry, had to meet product serialization and tracking regulations to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process and minimizing financial loss.

Aesica Pharmaceuticals was faced with an unexpected challenge when the compliance deadline for a new Chinese serialization regulation was accelerated from twelve-months to three-months. To meet the accelerated deadline, Aesica chose to upgrade to QAD EE, which helped Aesica meet the new serialization regulations.

“QAD has been a great partner to help Aesica meet the unexpectedly accelerated deadline from China,” said Maurizio Beninati, IT Manager Italy, Aesica Pharmaceuticals S.r.l. “We couldn’t have conquered this challenge without their help and expertise.”

Working with QAD, Aesica Pharmaceuticals met the accelerated regulation deadline through leveraging the enhanced serialization capability of QAD EE.

With the successful implementation, Aesica can now:

  • Identify each individual packaging unit down to the smallest sellable unit.
  • Aggregate individual unit serial numbers as packages are bundled, boxed and placed on shipping pallets.
  • Seamlessly track and trace each single pack of medication.
  • Report serial numbers to the required government agencies once products have been produced and imported.

About Aesica

Aesica Pharmaceuticals S.r.l. supplies contract development and contract manufacturing services for finished dose and active pharmaceutical ingredients to the world’s leading pharmaceutical companies and emerging biotechnology organizations. With headquarters in the United Kingdom, it is one of the country’s fastest growing companies. Aesica currently employs approximately 1,300 people at its headquarters in Newcastle upon Tyne and at manufacturing sites in Cramlington, Nottingham and Queenborough in the U.K., as well as Monheim and Zwickau in Germany and Pianezza, Italy. Aesica is a portfolio company of Silverfleet Capital, one of the leading European mid-market private equity firms, which invested in the business in October 2011. For additional information go to .